Search Results - "Minichmayr, Iris K."

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics by Wicha, Sebastian G., Märtson, Anne‐Grete, Nielsen, Elisabet I., Koch, Birgit C.P., Friberg, Lena E., Alffenaar, Jan‐Willem, Minichmayr, Iris K.

“…Therapeutic drug monitoring (TDM) and model‐informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in…”
Get full text

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study by Ehmann, Lisa, Zoller, Michael, Minichmayr, Iris K, Scharf, Christina, Maier, Barbara, Schmitt, Maximilian V, Hartung, Niklas, Huisinga, Wilhelm, Vogeser, Michael, Frey, Lorenz, Zander, Johannes, Kloft, Charlotte

“…Severe bacterial infections remain a major challenge in intensive care units because of their high prevalence and mortality. Adequate antibiotic exposure has…”
Get full text

Multistate modeling for survival analysis in critically ill patients treated with meropenem by Peng, Yaru, Minichmayr, Iris K., Liu, Han, Xie, Feifan, Friberg, Lena E.

“…Appropriate antibiotic dosing to ensure early and sufficient target attainment is crucial for improving clinical outcome in critically ill patients. Parametric…”
Get full text

Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings by Minichmayr, Iris K, Kappetein, Suzanne, Brill, Margreke J E, Friberg, Lena E

“…Pharmacokinetic-pharmacodynamic (PKPD) models have met increasing interest as tools to identify potential efficacious antibiotic dosing regimens in vitro and…”
Get full text

Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis by Ehmann, Lisa, Zoller, Michael, Minichmayr, Iris K., Scharf, Christina, Huisinga, Wilhelm, Zander, Johannes, Kloft, Charlotte

“…•Adequate dosing resulting in effective exposure is crucial for therapeutic success.•Renal function is a vital determinant for achieving effective antibiotic…”
Get full text

Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation by Minichmayr, Iris K., Friberg, Lena E.

“…•We studied whether meropenem (MEM) stability allows for continuous infusion (CI).•High- and low-dose CI regimens were simulated with a PK-PD model on P…”
Get full text

Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects by Minichmayr, Iris K., Aranzana-Climent, Vincent, Friberg, Lena E.

“…•One hundred and thirty-two publications on pharmacokinetic/pharmacodynamic (PKPD) models for time courses of antibiotic effects were reviewed.•Points to…”
Get full text

Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model by Minichmayr, Iris K, Roberts, Jason A, Frey, Otto R, Roehr, Anka C, Kloft, Charlotte, Brinkmann, Alexander

“…Optimal antibiotic exposure is a vital but challenging prerequisite for achieving clinical success in ICU patients. To develop and externally validate a…”
Get full text

Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment by Minichmayr, Iris K., Wicha, Sebastian G., Matzneller, Peter, Kloft, Charlotte, Zeitlinger, Markus

“…Background and Objective Ceftaroline fosamil is a β-lactam antibiotic approved as a 600 mg twice daily dose (≤1 h infusion, ‘standard dosing’) or a 600 mg…”
Get full text

Recent Advances Addressing the Challenges of Precision Dosing by Minichmayr, Iris K., Mizuno, Tomoyuki, Goswami, Srijib, Peck, Richard W., Polasek, Thomas M.

Get full text

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients by Minichmayr, Iris K., Schaeftlein, André, Kuti, Joseph L., Zeitlinger, Markus, Kloft, Charlotte

“…Objectives We aimed to assess linezolid pharmacokinetics in the plasma and interstitial space fluid (ISF) of patients with sepsis, diabetic foot infections or…”
Get full text

Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients” by Minichmayr, Iris K., Zeitlinger, Markus

“…[...]dosing adaptations based on target attainment at the site of infection would be desirable. [...]Colin and colleagues chose a populationPK model for their…”
Get full text

Concentrations of ceftazidime and avibactam in bile fluid-a prospective phase IIb study by Witowski, Andrea, Palmowski, Lars, Minichmayr, Iris K, Zeitlinger, Markus, Dorn, Christoph, Lier, Constantin, Adamzik, Michael, Nowak, Hartmuth, Rahmel, Tim

“…The rise in carbapenem-resistant bacteria and the limited number of effective antibiotics pose a major health-care threat. The combination of ceftazidime (CAZ)…”
Get full text

Getting the Dosage Right: A Vital Role for Clinical Pharmacology in the Era of Precision Medicine by Minichmayr, Iris K., Shebley, Mohamad, Graaf, Piet H., Venkatakrishnan, Karthik

Get full text

PKPD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MIC by Saporta, Raphaël, Nielsen, Elisabet I., Hansen, Jon U., Liepinsh, Edgars, Minichmayr, Iris K., Friberg, Lena E.

“…•Meropenem was tested in vivo against six bacterial strains with MICs>32 mg/L.•The developed PKPD model described the time course of meropenem effects.•MIC…”
Get full text

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety by Minichmayr, Iris K., Karlsson, Mats O., Jönsson, Siv

“…Purpose Pharmacometric models provide useful tools to aid the rational design of clinical trials. This study evaluates study design-, drug-, and…”
Get full text

Trends in Clinical Pharmacology and Therapeutics by Minichmayr, Iris K., Smith, D. Max, Giacomini, Kathleen M., Graaf, Piet H.

Get full text

Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials by Smith, D Max, Minichmayr, Iris K, Standing, Joseph F, Giacomini, Kathleen M, van der Graaf, Piet H, Peck, Richard W

Get full text

Therapeutic Innovations in Neuroscience: What’s New on the Horizon? by Minichmayr, Iris K., Ravenstijn, Paulien, Graaf, Piet H., Vamvakas, Spiros

Get full text

Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting by Greppmair, Sebastian, Brinkmann, Alexander, Roehr, Anka, Frey, Otto, Hagel, Stefan, Dorn, Christoph, Marsot, Amélie, El-Haffaf, Ibrahim, Zoller, Michael, Saller, Thomas, Zander, Johannes, Schatz, Lea Marie, Scharf, Christina, Briegel, Josef, Minichmayr, Iris K., Wicha, Sebastian G., Liebchen, Uwe

“…Purpose Inadequate piperacillin (PIP) exposure in intensive care unit (ICU) patients threatens therapeutic success. Model-informed precision dosing (MIPD)…”
Get full text